IFW



**CERTIFICATE OF MAILING** 

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 14, 2005.

Jane A. Walker

Date

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Peyman

Serial No.:

10/667,161

Filed:

September 19, 2003

Group Art Unit:

1615

Confirmation No.:

8452

Examiner:

Unknown

Title:

**OCULAR SOLUTIONS** 

Attorney Ref.:

PMAN-25

Cincinnati, Ohio 45202

June 14, 2005

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of candor and good faith imposed by 37 C.F.R. §1.56 and means of complying therewith according to 37 C.F.R. §\$1.97 and 1.98, the references listed on the attached form PTO-1449 are called to the attention of the United States Patent and Trademark Office in connection with the above-identified patent application.

The Examiner is urged to consider the cited references listed on the attached form PTO-1449, and to make an independent decision with respect to materiality.

Applicant does not believe there is any fee due with this submission.

Should any fees or surcharges be deemed necessary, Examiner has authorization to charge fees or credit any overpayment to Deposit Account No. 23-3000. The Examiner is invited to telephone the undersigned attorney if there are any questions or issues.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.

Beverly A. Lyman, Ph.D.

Reg. No. 41,961

2700 Carew Tower 441 Vine Street Cincinnati, OH 45202 513 241-2324 513 421-7269 (facsimile)

SUBSTITUTE FORM PTO-1449  U.S. DEPARTMENT OF PATENT AND TRADER									ATTY. DOCKET NO. PMAN/25			SERIAL NO. 10/667,161		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT							OIPE	×	APPLI	ICANT m Peyman		L		
(37 CFR 1.98	_	(Use several sheets if necessary)					&\			3	GROUP 1615			
(37 CFK 1.30	,(0))		U.S. PATENT					<b>4</b> /				1 1010		
EXAMINER		<del>1                                    </del>	-			ISSUE	TA TRADE			ì			FILING DATE	
INITIAL		PA	TENT	NUMBE	R	DATE	PATENTEE		CLASS		SUBCLASS		IF APPROPRIATE	
	A.A				ļ									
	A.B			Ш										
	A.C													
	A.D													
	A.E													
	A.F													
	A.G													
	A.H													
	A.I													
	A.J													
	A.K													
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS														
		DOCUMENT NUMBER			Р	UBLICATION DATE	COUNTRY OR PATENT OFFICE			CLASS	SUBCLASS		TRANSLATION (YES/NO)	
	A.L													
	A.M													
	A.N	2												
	A.O													
	A.P													
	A.Q													
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)														
	A.R	Grisola	Grisolano et al., Retinal Toxicity Study of Intravitreal Cyclosporin, Ophthalmic Surgery, March 1986, 17:155-156											
	A.S	Kiryu et al., In Vivo Evaluation of the Inhibitory Effects of Tacrolimus (FK506) on Leukocyte Accumulation During Retinal Ischemia Reperfusion Injury, ARVO 1998 Meeting, Ft. Lauderdale, FL, Poster Presentation 1247-B128												
-	A.T	Martin DF et al., Synergistic Effect of Rapamycin and Cyclosporin A in the Treatment of Experimental Autoimmune  Uveoretinitis, The Journal of Immunology, 1995, 154:922-927												
EXAMINER					D	DATE CONSIDERED								
EXAMINER: Include a cop	nitial if ci	tation co	nsider	ed, whe	ther or	r not in confor n to applicant.	mance. Drav	v line throug	h citatio	n only if not i	n conform	nance <u>ar</u>	not considered.	